News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.
The automated, whole-genome directional genomic hybridization system can measure de novo random, low-frequency, and complex structural variations.
The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.
The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.
The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
